Are patients undergoing treatment of hyperlipidaemia with statins the best candidates for early cardiac rehabilitation? can influence the safety of statin therapy. Such a procedure will help clinicians to achieve the maximal benefit of cardiac rehabilitation with minimal risk of serious side effects of simul- taneously conducted hyperlipidaemia treatment. In our opinion, the benefits of the secondary prevention of CHD achieved with statins seem to outweigh the hazards of this kind of therapy. However, the question as to whether patients taking statins are the best candidates for early cardiac rehabilitation still remains unanswered. R e f e r e n c e s 1. Rudnicki S. Rehabilitacja w chorobach układu krążenia i po operacjach serca. In: Kwolek A. Rehabilitacja medyczna [Polish]. Wydawnictwo Medyczne Urban&Partner, Wrocław 2003; 309-38. 2. Narodowy Program Profilaktyki i Leczenia Chorób Układu Sercowo-Naczyniowego POLKARD. Raport o stanie rehabilitacji kardiologicznej w Polsce. Gdańsk, Łodź, Poznań. Tarnowskie Góry. Ustroń. Warszawa, sierpień 2004 [Polish]. Available at: www.polkard.org. 3. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of A to Z trial. JAMA 2004; 292: 1307-16. 4. Barylski M, Mikhailidis DP, Rysz J, Banach M. Risk factor modification after ACS. Non-pharmacological mana- gement after acute coronary syndromes. Arch Med Sci 2010; 6: S64-75. 5. Tałałaj-Pastuszak B, Wysokiński A. Wczesna rehabilitacja kardiologiczna w „Szpitalu Uzdrowiskowym” w Nałę- czowie [Polish]. Ann Univ M Curie Skłodowska, Sectio D, 2005, 60, 16, 560: 485-488. 6. Packard CJ. Risk factor modification after ACS. Benefits of lipid regulation in acute coronary syndrome. Arch Med Sci 2010; 6: S76-82. 7. Wainwright G, Mascitelli L, Goldstein MR. Cholesterol- lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes? Arch Med Sci 2009; 5: 289-95. 8. Angelopoulos J, Krassakopoulos N, Natanson R, Boukas S, Sampalis JS. Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Arch Med Sci 2009; 5: 347-63. 9. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90. 10. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO Study. Cardiovasc Drugs Ther 2005; 19: 403-14. 11. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid- lowering drugs. JAMA 2004; 292: 2585-90. 12. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-8. 13. Lane R, Phillips M. Rhabdomyolysis. BMJ 2003; 327: 115-6. 14. Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-57. 15. Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005; 165: 2671-6. 16. Antons KA, Williams CD, Baker SK, et al. Clinical per- spectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9. 17. Wortmann RL. Dose-related stain myopathy. Is it an issue? Clev Clinic J Med 2005; 72: 751-6. 18. Kędzia A, Krysiak R, Madej A, et al. Is every case of muscale damage during hypolipemic therapy the side effect of this therapy? A case report. Pol Arch Med Wewn 2007; 117: 473-6. 19. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58: 56-60. 20. Bizzaro N, Bagolin E, Milani L, Ceresem C, Finco B. Massive rhabdomyolysis and simvastatin. Clin Chem 1992; 38: 1504. 21. Unnikrishnan D. Exertion-induced rhabdomyolysis in a patent on statin therapy. Nephrol Dial Transplant 2005; 20: 244. 22. Hong YH, Won HS, Kim DI, et al. Rhabdomyolysis asso- ciated with statin medication, exercise and sauna. Korean Circ J 2008; 38: 284-6. 23. Vladutiu GD, Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20: 648-55. 24. Małecki R. Rabdomioliza – postępowanie w warunkach opieki podstawowej [Polish]. Kardiologia na co Dzień 2007; 2: 64-68. 25. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Stag- gers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolizm 1997; 46: 1206-10. 26. Coen PM, Flynn MG, Markofski MM, Brandt DP, Hannemann RE. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metab Clin Exper 2009; 58: 1030-8. 27. Sinzinger H, O’Grady JO. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2005; 57: 525-8. 28. Dybała A, Grzywa-Celińska A, Mosiewicz J, Myśliński W. Myopathy in the curse of hypolipemic therapy in patient undergoing early cardiac rehabilitation after the percutation after the percutaneous coronary intervention – a case report. Pol Merk Lek 2009; 27: 226-8. Arch Med Sci 5, October / 2011 759